Advertisement

Alefacept

  • Giuseppe TridenteEmail author
Chapter

Abstract

Alefacept (Amevive®, Astellas) is a recombinant dimeric fusion protein combining the Fc fragment of human IgG1 with the CD2-binding portion of the human leukocyte antigen-3 (LFA-3).

Keywords

Hypersensitivity Reaction Human IgG1 Plaque Psoriasis Injection Site Reaction Chronic Plaque Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Alefacept (Amevive®) Prescribing Information Astella, May 2012Google Scholar
  2. 2.
    Bhutani T, Kamangar F, Zitelli K et al (2012) Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. J Dermatol Treat doi: 10.3109/09546634.2012.672712
  3. 3.
    Lui H, Gulliver W, Hong TJ et al (2012) A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. J Drugs Dermatol 11:929–937PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations